Roman Butler Fullerton & Co. Takes Position in Chemed Co. (NYSE:CHE)

Roman Butler Fullerton & Co. bought a new stake in shares of Chemed Co. (NYSE:CHE) during the 3rd quarter, Holdings Channel reports. The fund bought 479 shares of the company’s stock, valued at approximately $289,000.

Other hedge funds have also recently made changes to their positions in the company. BI Asset Management Fondsmaeglerselskab A S purchased a new position in shares of Chemed during the first quarter valued at approximately $1,064,000. ProShare Advisors LLC increased its stake in shares of Chemed by 6,288.9% during the first quarter. ProShare Advisors LLC now owns 50,600 shares of the company’s stock valued at $32,482,000 after buying an additional 49,808 shares during the period. Sei Investments Co. increased its stake in shares of Chemed by 4.5% during the first quarter. Sei Investments Co. now owns 41,336 shares of the company’s stock valued at $26,535,000 after buying an additional 1,780 shares during the period. Susquehanna Fundamental Investments LLC purchased a new position in shares of Chemed during the first quarter valued at approximately $4,512,000. Finally, Quantbot Technologies LP increased its stake in shares of Chemed by 167.3% during the first quarter. Quantbot Technologies LP now owns 2,999 shares of the company’s stock valued at $1,925,000 after buying an additional 1,877 shares during the period. 95.85% of the stock is owned by hedge funds and other institutional investors.

Chemed Stock Down 1.3 %

NYSE CHE opened at $525.03 on Tuesday. Chemed Co. has a twelve month low of $523.33 and a twelve month high of $654.62. The firm has a market capitalization of $7.90 billion, a PE ratio of 26.53, a P/E/G ratio of 2.19 and a beta of 0.46. The stock’s 50 day moving average is $584.37 and its 200 day moving average is $567.22.

Chemed (NYSE:CHE) last released its quarterly earnings results on Tuesday, October 29th. The company reported $5.64 earnings per share for the quarter, missing the consensus estimate of $5.76 by ($0.12). Chemed had a net margin of 12.69% and a return on equity of 27.86%. The firm had revenue of $606.18 million for the quarter, compared to the consensus estimate of $612.22 million. During the same quarter in the prior year, the firm earned $5.32 earnings per share. The company’s revenue for the quarter was up 7.4% compared to the same quarter last year. On average, research analysts anticipate that Chemed Co. will post 22.41 earnings per share for the current year.

Insiders Place Their Bets

In other Chemed news, Director George J. Walsh III sold 400 shares of the business’s stock in a transaction on Thursday, September 26th. The stock was sold at an average price of $597.47, for a total value of $238,988.00. Following the sale, the director now directly owns 3,046 shares of the company’s stock, valued at approximately $1,819,893.62. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In other Chemed news, Director George J. Walsh III sold 400 shares of the business’s stock in a transaction on Thursday, September 26th. The stock was sold at an average price of $597.47, for a total value of $238,988.00. Following the sale, the director now directly owns 3,046 shares of the company’s stock, valued at approximately $1,819,893.62. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Nicholas Michael Westfall sold 1,713 shares of the company’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $569.35, for a total value of $975,296.55. Following the transaction, the executive vice president now directly owns 6,109 shares in the company, valued at approximately $3,478,159.15. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 5,144 shares of company stock valued at $3,002,419. 3.32% of the stock is currently owned by corporate insiders.

Chemed Company Profile

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.